Summary
Terguride, is an 8 — alpha — ergoline derived from lisuride, acts as a partial dopamine (DA) agonist.
The effect and tolerance of terguride has been investigated by an acute administration of 0.2 mg p.o. to 8 normal women, 8 patients with hyperprolactinaemia and 8 women with puerperal hyperprolactinaemia. Prolactin (PRL) levels were markedly suppressed in all subjects, with no significant differences between the groups.
Treatment for 5 days with terguride 0.4 mg/day or 0.8 mg/day was studied as an inhibitor of lactation. PRL levels were suppressed in a dose-related manner. No untoward side-effects were noted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Flückiger E, Briner U, Enz A, Markstein R, Vigouret JM (1983) Dopaminergic ergot compounds: An overview. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Raven Press, New York, pp 1–9
Wachtel H, Dorow R (1983) Dual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci 32: 421–432
Auskovà M, Rezàbek K, Zikàn V, Semonski M (1974) Laktationshemmende Wirkung von N-(D-6-Methyl-8-Isoergolin-I-yl)-N-N′-Diäthylharnstoff (VUFB-6638). Experientia 30: 393–394
Dlabac A, Krejci I (1980) Central dopaminergic effects of ergot derivatives. Acta Neurol [Suppl] 22: 208–209
Dorow R, Breitkopf M, Graf KJ, Horowski R (1983) Neuroendocrine effects of lisuride and its 9,10-dihydrogenated analog in healthy volunteers. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds). Raven Press, New York, pp 161–174
Besser GM, Wass JAH, Grossman A, Moult PJA, Bouloux P (1983) Hormonal and clinical effects of dopamine agonists. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds). Raven Press, New York, pp 239–254
De Cecco L, Venturini PL, Ragni N, Valenzano M, Costantini S, Horowski R (1983) Dopaminergic ergots in lactation and cycle disturbances. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds). Raven Press, New York, pp 291–299
Kehr W, Wachtel H, Schneider HH (1983) Dopaminergic and antidopaminergic properties of ergolines structurally related to lisuride. Acta Pharm Suec [Suppl 2]: 98–110
Utian WH, Begg G, Uinik AI, Paul M (1975) Effects of bromocriptine and diclorotrianisene in inhibition of lactation and serum prolactin. A comparative double blind study. Br J Obstet Gynaecol 82: 755–759
De Cecco L, Venturini PL, Ragni N, Rossato P, Maganza C, Gaggero G, Horowski R (1979) Effect of lisuride on inhibition of lactation and serum prolactin. Br J Obstet Gynaecol 86: 905–908
Venturini PL, Horowski R, Maganza C, Morano S, Pedretti E, Ragni N, Semino F, De Cecco L (1981) Effects of lisuride and bromocriptine on inhibition of lactation and serum prolactin levels: comparative double blind study. Eur J Obstet Gynecol Reprod Biol 11: 395–400
Schachter M, Bèdard P, Debono AG, Jenner P, Marsden CD, Price P, Parkes JD, Keenan J, Smith B, Rosenthaler J, Horowski R, Dorow R (1980) The role of D1 and D2 receptors. Nature 286: 157–159
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Venturini, P.L., Horowski, R., Valenzano, M. et al. Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women. Eur J Clin Pharmacol 30, 195–197 (1986). https://doi.org/10.1007/BF00614302
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00614302